Amplia's Narmafotinib Shows Strong Efficacy in Pancreatic Cancer Trial
Event summary
- Amplia Therapeutics presented mature data from the ACCENT trial at the AACR annual meeting on April 22, 2026.
- Narmafotinib combined with chemotherapy showed an 8% complete response rate vs. 0.2% for chemotherapy alone.
- Median overall survival improved to 11.1 months, a 2+ month increase over standard treatment.
- Disease Control Rate reached 70%, significantly higher than the 50% for chemotherapy alone.
- Amplia plans to shift to daily dosing in subsequent trials based on observed tolerability.
The big picture
Amplia's positive ACCENT trial results position narmafotinib as a potential game-changer in pancreatic cancer treatment, where survival outcomes remain poor. The data supports FAK inhibition as a viable therapeutic approach, aligning with broader industry trends toward precision oncology and combination therapies. Amplia's next steps will determine whether it can capitalize on this momentum in a competitive oncology market.
What we're watching
- Clinical Validation
- Whether the improved dosing regimen can enhance narmafotinib's efficacy in future trials.
- Regulatory Pathway
- The pace at which Amplia advances toward pivotal studies based on ACCENT data.
- Competitive Positioning
- How Amplia's combination strategy with kRAS inhibitors differentiates it in pancreatic cancer treatment.
Related topics